Drug Trial Radar · NCT00352144
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
Last checked: Nov 20, 2026Latest source record: Feb 22, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
830
Actual
Start
Oct 2003
Primary completion
Oct 2004
Study completion Oct 2004
Sponsor
- Lead sponsor
- Sumitomo Pharma America, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the long-term efficacy of eszopiclone administered for up to 6 months in subjects with primary insomnia on subjective sleep measures, compared to placebo.
Conditions
- Primary Insomnia
Interventions
EszopicloneDrug
Eszopiclone 3 mg
PlaceboDrug
Placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Average of Subjective Sleep LatencyTime frame: Days -14, 1, 30, 60, 90, 120, 150, 180
Locations
58 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Huntsville, Alabama
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Anaheim, California
Site not named
Irvine, California
Site not named
Oakland, California
Site not named
Redlands, California
Site not named
San Diego, California
Site not named
Aurora, Colorado
Site not named
Denver, Colorado
Site not named
Longmont, Colorado
Site not named
Pueblo, Colorado
Site not named
Clearwater, Florida
Site not named
Jacksonville, Florida
Site not named
Jupiter, Florida
Site not named
Naples, Florida
Site not named
Orlando, Florida
Site not named
Pembroke Pines, Florida
Site not named
Pinellas Park, Florida
Site not named
St. Petersburg, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Blairsville, Georgia
Site not named
Chicago, Illinois
Site not named
Elk Grove Village, Illinois
Site not named
Northbrook, Illinois
Site not named
Evansville, Indiana
Site not named
Olathe, Kansas
Site not named
Prairie Village, Kansas
Site not named
Chevy Chase, Maryland
Site not named
Frederick, Maryland
Site not named
Newton, Massachusetts
Site not named
Kansas City, Missouri
Site not named
St Louis, Missouri
Site not named
Lincoln, Nebraska
Site not named
Las Vegas, Nevada
Site not named
Hamilton, New Jersey
Site not named
New York, New York
Site not named
Cary, North Carolina
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.